Biotest Aktiengesellschaft (FRA:BIO)

Germany flag Germany · Delayed Price · Currency is EUR
42.20
-0.40 (-0.94%)
Last updated: Jun 6, 2025
1.44%
Market Cap 1.40B
Revenue (ttm) 635.20M
Net Income (ttm) -24.50M
Shares Out n/a
EPS (ttm) -0.63
PE Ratio n/a
Forward PE 23.49
Dividend 0.04 (0.09%)
Ex-Dividend Date Jul 3, 2025
Volume n/a
Average Volume 454
Open 42.20
Previous Close 42.60
Day's Range 42.20 - 42.20
52-Week Range 40.40 - 43.20
Beta n/a
RSI 48.94
Earnings Date May 12, 2025

About FRA:BIO

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. It operates through three segments: European Union, Rest of the World, and Stateless. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company’s produ... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1946
Employees 2,495
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol BIO
Full Company Profile

Financial Performance

In 2024, FRA:BIO's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.

Financial Statements

News

EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG

EQS-Ad-hoc: Biotest AG / Key word(s): Personnel Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG 28-May-2025 / 17:00 CET/CEST Disclosure of an inside information acc. to Article 1...

9 days ago - Wallstreet:Online

Biotest Affirms 2025 Guidance with Confidence

Biotest AG's financial landscape shifts dramatically in Q1 2025, marked by a steep 42.3% sales drop and significant profit losses, driven by reduced technology services for Grifols, S.A. Jetzt den vol...

25 days ago - Wallstreet:Online

EQS-News: Biotest confirms Guidance for 2025

EQS-News: Biotest AG / Key word(s): Quarterly / Interim Statement Biotest confirms Guidance for 2025 12.05.2025 / 17:35 CET/CEST The issuer is solely responsible for the content of this announcement. ...

25 days ago - Wallstreet:Online

EQS-WpÜG: Tender Offer / Target company: Biotest AG; Bidder: Grifols Biotest Holdings GmbH

EQS-WpÜG: Grifols Biotest Holdings GmbH / Tender Offer Tender Offer / Target company: Biotest AG; Bidder: Grifols Biotest Holdings GmbH 31.03.2025 / 08:43 CET/CEST Dissemination of an announcement acc...

2 months ago - Wallstreet:Online

EQS-Adhoc: Biotest AG: Delisting agreement and announced delisting tender offer

EQS-Ad-hoc: Biotest AG / Key word(s): Delisting Biotest AG: Delisting agreement and announced delisting tender offer 31-March-2025 / 08:40 CET/CEST Disclosure of an inside information acc. to Article ...

2 months ago - Wallstreet:Online

Biotest AG Boosts Sales by 6% in 2024

Biotest AG's financial journey in 2024 paints a picture of both triumph and challenge. With a notable 6.1% sales increase, the company reached new heights at €726.2 million. While EBIT hit the forecas...

2 months ago - Wallstreet:Online

EQS-News: Biotest AG increases sales by 6% in financial year 2024

EQS-News: Biotest AG / Key word(s): Annual Report Biotest AG increases sales by 6% in financial year 2024 31.03.2025 / 07:00 CET/CEST The issuer is solely responsible for the content of this announcem...

2 months ago - Wallstreet:Online

EQS-Adhoc: Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future.

EQS-Ad-hoc: Biotest AG / Key word(s): Personnel Biotest AG: CFO Martin Möller to leave Biotest as planned at the end of his contract. Position of CFO to be filled in the near future. 06-March-2025 / 0...

3 months ago - Wallstreet:Online